|
Volumn 37, Issue 11, 2001, Pages 1352-1358
|
A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma
|
Author keywords
5 Fluorouracil; Chemotherapy; Eniluracil; Inoperable hepatocellular carcinoma
|
Indexed keywords
5 ETHYNYLURACIL;
ANTHRACYCLINE;
FLUOROURACIL;
ADULT;
AGED;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE COURSE;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERANCE;
FEMALE;
FOLLOW UP;
HUMAN;
LIVER CELL CARCINOMA;
MALE;
MULTICENTER STUDY;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGNOSIS;
RESPONSE TIME;
SIDE EFFECT;
ADMINISTRATION, ORAL;
ADULT;
AGED;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, HEPATOCELLULAR;
FEMALE;
FLUOROURACIL;
FOLLOW-UP STUDIES;
HUMANS;
LIVER NEOPLASMS;
MALE;
MIDDLE AGED;
SURVIVAL RATE;
URACIL;
|
EID: 0034954843
PISSN: 09598049
EISSN: None
Source Type: Journal
DOI: 10.1016/S0959-8049(01)00100-9 Document Type: Conference Paper |
Times cited : (26)
|
References (30)
|